Can tissue-free ctDNA detect breast cancer relapse early?
A retrospective c-TRAK TN analysis found tissue-free ctDNA predicted TNBC relapse, but clinical benefit and NHS implementation remain unproven.
Hazard ratios hide who benefits from anthracyclines in early breast cancer
Hazard ratios assume uniform benefit, but anthracycline’s absolute benefit and cardiac harm both depend on baseline risk, not the ratio itself.